Redhill Biopharma Ltd
NASDAQ:RDHL

Watchlist Manager
Redhill Biopharma Ltd Logo
Redhill Biopharma Ltd
NASDAQ:RDHL
Watchlist
Price: 1.955 USD 2.2% Market Closed
Market Cap: 4.5m USD

Relative Value

RDHL doesn't have a meaningful market cap.

The Relative Value of one RDHL stock under the Base Case scenario is 8.563 USD. Compared to the current market price of 1.955 USD, Redhill Biopharma Ltd is Undervalued by 77%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

RDHL Relative Value
Base Case
8.563 USD
Undervaluation 77%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
95
vs Industry
85
Median 3Y
2.5
Median 5Y
11.8
Industry
2.5
Forward
0.1
vs History
vs Industry
46
Median 3Y
-0.6
Median 5Y
-16.9
Industry
21.6
vs History
vs Industry
Median 3Y
-1.5
Median 5Y
-17.7
Industry
16.7
vs History
vs Industry
Median 3Y
-1.4
Median 5Y
-13.2
Industry
24
vs History
vs Industry
0
Median 3Y
8.4
Median 5Y
40.4
Industry
2.2
vs History
95
vs Industry
72
Median 3Y
2.2
Median 5Y
11.6
Industry
2.7
Forward
-0
vs History
95
vs Industry
69
Median 3Y
4.9
Median 5Y
23
Industry
5.3
vs History
vs Industry
53
Median 3Y
1.4
Median 5Y
-14.5
Industry
12.9
vs History
vs Industry
48
Median 3Y
1.7
Median 5Y
-11.7
Industry
16.3
Forward
0
vs History
vs Industry
58
Median 3Y
-1
Median 5Y
-17.2
Industry
15.2
vs History
vs Industry
44
Median 3Y
-1
Median 5Y
-17.1
Industry
17.7
vs History
95
vs Industry
75
Median 3Y
1.9
Median 5Y
6.1
Industry
1.9

Multiples Across Competitors

RDHL Competitors Multiples
Redhill Biopharma Ltd Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
IL
Redhill Biopharma Ltd
NASDAQ:RDHL
4.5m USD 0.6 -0.5 0 0
US
Eli Lilly and Co
NYSE:LLY
748.5B USD 15.3 67.4 36.2 39.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
396.4B USD 4.4 18.2 13.3 17.4
DK
Novo Nordisk A/S
CSE:NOVO B
1.9T DKK 6.3 18.1 12.6 14.4
CH
Roche Holding AG
SIX:ROG
205B CHF 3.4 24.7 9.3 10.9
CH
Novartis AG
SIX:NOVN
185.6B CHF 4.4 18 10.6 14.2
UK
AstraZeneca PLC
LSE:AZN
161.9B GBP 4 27.9 130.7 197
US
Merck & Co Inc
NYSE:MRK
207.4B USD 3.2 11.9 8.8 10.7
IE
Endo International PLC
LSE:0Y5F
183.8B USD 79.3 -62.9 292.4 733.2
US
Pfizer Inc
NYSE:PFE
139.9B USD 2.2 17.7 7.6 10.7
P/E Multiple
Earnings Growth PEG
IL
Redhill Biopharma Ltd
NASDAQ:RDHL
Average P/E: 25.5
Negative Multiple: -0.5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
67.4
49%
1.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
18.2
27%
0.7
DK
Novo Nordisk A/S
CSE:NOVO B
18.1
18%
1
CH
Roche Holding AG
SIX:ROG
24.7
32%
0.8
CH
Novartis AG
SIX:NOVN
18
17%
1.1
UK
AstraZeneca PLC
LSE:AZN
27.9
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11.9
17%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -62.9 N/A N/A
US
Pfizer Inc
NYSE:PFE
17.7
30%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IL
Redhill Biopharma Ltd
NASDAQ:RDHL
Average EV/EBITDA: 397.1
0
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
36.2
30%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
13.3
7%
1.9
DK
Novo Nordisk A/S
CSE:NOVO B
12.6
13%
1
CH
Roche Holding AG
SIX:ROG
9.3
5%
1.9
CH
Novartis AG
SIX:NOVN
10.6
5%
2.1
UK
AstraZeneca PLC
LSE:AZN
130.7
10%
13.1
US
Merck & Co Inc
NYSE:MRK
8.8
8%
1.1
IE
E
Endo International PLC
LSE:0Y5F
292.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.6
2%
3.8
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IL
Redhill Biopharma Ltd
NASDAQ:RDHL
Average EV/EBIT: 1 704.6
0
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39.5
32%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
17.4
13%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
14.4
14%
1
CH
Roche Holding AG
SIX:ROG
10.9
6%
1.8
CH
Novartis AG
SIX:NOVN
14.2
10%
1.4
UK
AstraZeneca PLC
LSE:AZN
197
23%
8.6
US
Merck & Co Inc
NYSE:MRK
10.7
11%
1
IE
E
Endo International PLC
LSE:0Y5F
733.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.7
10%
1.1